Biofrontera is a pharmaceuticals business based in the US. Biofrontera shares (BFRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biofrontera employs 149 staff and has a trailing 12-month revenue of around $28 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.94 |
|---|---|
| 52-week range | $0.00 - $0.00 |
| 50-day moving average | $2.89 |
| 200-day moving average | $4.65 |
| Wall St. target price | $8.50 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.61 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.94 from 2022-05-06
| 1 week (2024-07-16) | N/A |
|---|---|
| 1 month (2024-06-23) | N/A |
| 3 months (2024-04-23) | N/A |
| 6 months (2024-01-23) | N/A |
| 1 year (2023-07-23) | N/A |
|---|---|
| 2 years (2022-07-23) | N/A |
| 3 years (2021-07-27) | 6.3 |
| 5 years (2019-07-23) | 15.2865 |
Valuing Biofrontera stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biofrontera's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biofrontera's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 million.
The EBITDA is a measure of a Biofrontera's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $28 million |
|---|---|
| Gross profit TTM | $26.8 million |
| Return on assets TTM | -10.51% |
| Return on equity TTM | -124.08% |
| Profit margin | -55.98% |
| Book value | $0.76 |
| Market Capitalization | $75.7 million |
TTM: trailing 12 months
We're not expecting Biofrontera to pay a dividend over the next 12 months.
Over the last 12 months, Biofrontera's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 1.548. This would suggest that Biofrontera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co.
Learn how to invest in Cathie Wood’s ARK Venture Fund in 5 easy steps.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
Explore the best bonuses for opening a new brokerage account.
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.